Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study

Documents similaires

• The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
  par: Landray, M, et autres
  Publié: (2006)
• First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
  par: Baigent, C, et autres
  Publié: (2005)
• Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the first UK-Heart and Renal Protection (UK-HARP-1) study.
  par: Baigent, C, et autres
  Publié: (2002)
• Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
  par: Alexander, W, et autres
  Publié: (2011)
• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
  par: Baigent, C, et autres
  Publié: (2011)